Published April 2015 | Version Supplemental Material
Journal Article Open

Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis

Abstract

Sporadic inclusion body myositis (sIBM) has clinical, pathologic and pathomechanistic overlap with some inherited muscle and neurodegenerative disorders. In this study, DNA from 79 patients with sIBM was collected and the sequencing of 38 genes associated with hereditary inclusion body myopathy (IBM), myofibrillar myopathy, Emery–Dreifuss muscular dystrophy, distal myopathy, amyotrophic lateral sclerosis and dementia along with C9orf72 hexanucleotide repeat analysis was performed. No C9orf72 repeat expansions were identified, but; 27 rare (minor allele frequency <1%) missense coding variants in several other genes were identified. One patient carried a p.R95C missense mutation in VCP and another carried a previously reported p.I27V missense mutation in VCP. Mutations in VCP cause IBM associated with Paget's disease of the bone (PDB) and fronto-temporal dementia (IBMPFD). Neither patient had a family history of weakness or manifested other symptoms reported with VCP mutations such as PDB or dementia. In vitro analysis of these VCP variants found that they both disrupted autophagy similar to other pathogenic mutations. Although no clear genetic etiology has been implicated in sIBM pathogenesis, our study suggests that genetic evaluation in sIBM may be clinically meaningful and lend insight into its pathomechanism.

Additional Information

© 2014 Elsevier. Received 17 October 2014, Revised 15 December 2014, Accepted 28 December 2014, Available online 6 January 2015. We thank Amir Dori, Taha Bali, Cindy Ly, Arun Varadacharry, Paul Cooper, and Leo Wang for help with patient assessment. Supported by a research agreement from Ultragenyx Pharmaceuticals, Novato CA to CCW. Other funding included NIH AG031867 (CCW), AG042095 (CCW), NS055980 (RHB), NS069669 (RHB), and NS075094 (MBH). The Muscular Dystrophy Association (CCW), the Myositis Association (CCW), and the Hope Center for Neurological Disorders (CCW and MBH). RHB holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. Dr. Weihl had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Attached Files

Supplemental Material - 1-s2.0-S0960896614007305-mmc1.zip

Supplemental Material - 1-s2.0-S0960896614007305-mmc2.docx

Files

1-s2.0-S0960896614007305-mmc1.zip

Files (286.8 kB)

Name Size
md5:e273c54e6207793b260926962553db53
269.0 kB Preview Download
md5:21d500cb89b982d7235cffb31eddcee2
17.8 kB Download

Additional details

Identifiers

Eprint ID
114052
Resolver ID
CaltechAUTHORS:20220323-565912000

Funding

Ultragenyx Pharmaceuticals
NIH
AG031867
NIH
AG042095
NIH
NS055980
NIH
NS069669
NIH
NS075094
Muscular Dystrophy Association
Myositis Association
Hope Center for Neurological Disorders
Burroughs Wellcome Fund

Dates

Created
2022-03-24
Created from EPrint's datestamp field
Updated
2022-03-24
Created from EPrint's last_modified field